

1/13

10/501098

M Cyplasin




Fig. 1

BEST AVAILABLE COPY

10/501098

1 10 20 30 2/13
+ + + + 40

(L)
MAVRFLAPGLLTATLVSGRTVCESKQECDAAQCDKTLDV L
MAVRFLAPGLLTATLVSGRTVCESKQECDAAQCDKTLDV S

(T) (E)
AIVGAGAAGAYSAYLLRNKGQNIGVFEFCDRVGGRLFTYQ L
AIVGAGAAGAYSAYLLRNKGQNIGVFEFCDRVGGRLFTYQ S

(H)
LPNTPDVQLELGGMRYITGAHNLLLEGVVVRQLGLTPVVFT E L
LPNTPDVQLELGGMRYITGAHNLLLEGVVVRQLGLTPVVFT E S

GFGKLGRTTRYYLRGQSLTFQEVLTDVVPYNTVAEKQNQD L
GFGKLGRTTRYYPRGQSLTFQEALTGDVVPYNTVAEKQNQD S

NIFAFYLKELTRFDVGDFVTREQLLKLRLVSDGRLLYQLT L
NIFAFYLKELTRFDVGDFVTREQLLKLRLASDGRPLYQLT S

FDEALDLVASPEGKEFARDIHVTTEVSDDANAVSFDDH L
FDEALDLVASPEGKEFARDIHVTTEVSDDANAVSFDDH S

(L)
LGEDGVGEEIHTVQEGMOKVPEQLLRAFGNSSVFGHRVFT L
LGEDGVGEEIHTVQEGMOKVPEQPLRAFGNSSVFGHRVFT S

NLQLKAIRSKSDKSHVLYFRTTSTVDGKTTILKFEPLQKV L
NLQLKAIRAKSDKSHVPPYFRPTSTVDGKTTILKFEPLQKV S

(A)
CTROIILALPVFALMQVDWPPPLRENRAQKAYGAVRTIPAS L
CARQIILALPVFALMQVDWPPPLRENRAQKAYGAVRTIPAS S
KVFMTFDQFWLQNDVTDFPAFVTKGDTTFSQMYDWKKSE L
KVFMTFDQFWLQNDVTDFPAFVTKGDTTFSQMYDWKKPN S

ASGDYIILIASYADGNNTLFQRVLRDQGEPINGSEAGAHIV L
* VSGDYIILIASYADGSTQFWI S
SEPLKNQILDHLADAFGVPRSDIQEPKTAVSKFWTDYPFG L
CGWITWRAGYHFDDVMNTMRRPSLTDEVYVVGADYSWGLI L
SSWVEGALETSYEVIDTYFKSERSHNVQPPSHMASHVG L

Fig. 2(a)

GCC TAC CTT TTG AGG AAT AAA GGT CAG AAC
 ATC GGG GTC TTC GAA TTC TGT GAC AGA GTG
 GGT GGT CGG CTG TTC ACC TAT CAG TTG CCT
 AAT ACC CCC GAC GTG CAG CTG GAA CTG GGG
 GGG ATG CGG TAC ATC ACC GGC GCT CAT AAC
 CTG CTC GAG GGA GTC GTT CGT CAG CTG GGA
 CTG ACC CCA GTA GTG TTT ACA GAA GGC TTC
 GGT AAG CTG GGC CGT ACA CGC TAT TAC CTG
 AGG GGA CAG TCC CTG ACC TTC CAG GAA GTG
 CTG ACA GGC GAC GTG CCA TAC AAC CTT ACC
 GTC GCG GAG AAG CAG AAC CAG GAC AAT ATT
 TTC GCC TTC TAT CTC AAG GAA CTA ACC CGT
 TTC GAC GTA GGC GAC GGT TTC GTG ACC AGA
 GAA CAA CTG CTG AAA CTG CGC GTC AGC GAT
 GGG AGG CTC CTC TAC CAA CTG ACG TTC GAC
 GAA GCC CTG GAC CTG GTA GCA TCG CCG GAA
 GGT AAA GAA TTT GCC AGG GAC ATT CAC GTG
 TTT ACG ACG GAG GTT TCA GAC GAC GCC AAC
 GCG GTT TCG GTG TTC GAC GAC CAC TTA GGT
 GAG GAC GGC GTA GGC GAG GAG ATC CAT ACC
 GTG CAA GAA GGA ATG CAG AAA GTA CCG GAG
 CAA CTG CTG CGT GCA TTT GGA AAC AGT TCC
 GTC TTC GGC CAC AGG GTC TTC ACT AAC CTG
 CAA CTG AAA GCA ATT CGA AGC AAA TCC GAC
 AAG AGC CAC GTC CTG TAC TTT AGG ACC ACC
 TCC ACG GTT GAC GGC AAA ACA ACA ATT CTC
 AAA TTC GAG CCG CTG CAG AAG GTC TGC ACG
 CGT CAG ATT ATC CTA GCT CTG CCT GTG TTC
 GCC CTC ATG CAG GTC GAT TGG CCT CCC CTG
 CGT GAG AAT CGG GCG CAG AAG GCG TAC GGC
 GCG GTC AGG ACC ATT CCA GCG AGC AAG GTC
 TTC ATG ACG TTC GAC CAA CCG TGG TGG CTT
 CAG AAC GAT GTG ACA GAC TTC CCA GCG TTT
 GTG ACC AAA GGA GAC ACC ACT TTC TCG CAA
 ATG TAC GAC TGG AAA AAG TCC GAG GCT TCT
 GGT GAC TAC ATC CTC ATC GCT TCG TAC GCC
 GAC GGC AAC AAT ACC CTC TTC CAG AGG GTG
 CTG CGC GAC CAA GGG GAG CCG ATC AAC GGC
 AGT GAA GCC GGC GCC CAC ATC GTG TCC GAG
 CCC CTT AAG AAC CAA ATT TTG GAC CAC CTC
 GCG GAC GCG TTT GGC GTC CCC CGT TCG GAC
 ATT CAG GAG CCC AAA AGC GCG GTC AGC AAG
 TTT TGG ACT GAC TAC CCG TTT GGG TGT GGA
 TGG ATT ACA TGG CGG GCC GGC TAC CAC TTC
 GAC GAT GTG ATG AAC ACC ATG CGC AGA CCC
 TCA CTC ACC GAC GAG GTC TAC GTT GTG GGT
 GCG GAC TAC TCT TGG GGC CTT ATT TCT TCC
 TGG GTG GAA GGC GCC CTG GAA ACC TCC TAC
 GAG GTA ATC GAT ACA TAC TTC AAA AGC GAG
 CGG TCA CAT AAT GTG CAA CCT CCA AGC CAC
 ATG GCC TCC CAC GTG GGC

Fig. 2(b)

4/13

10/501098




Fig. 3

5/13

10/501098




Fig. 4

10/501098

Untreated

Genuine cyplasin

Recombinant cyplasin (EGFP)




Fig. 5




Fig. 6

8/13

10/501098




Fig. 7

10/501098

9/13




Fig. 8

10/13

10/501098




Fig. 9

11/13

10/501098




Fig. 10

AYLLRNKGQNIGVFEFCDRYGGRLFTYQLPNTPDVQLELGGMRYITGAHNLLEGVVRQLG
 10 20 30 40 50 60
 LTPVVFTEGFGKLGRTYYLRGQSLTFQEVLTDVYPNLVAEKQNQDNIFAFYLKELTR
 70 80 90 100 110 120
 FDVGDFVTREQLLKLRVSDGRLLYQLTFDEALDLVASPEGKEFARDIHVFTTEVSDDAN
 130 140 150 160 170 180
 AVSVFDDHLGEDGVGEEIHTVQEGMOKVPEQLLRAFGNSSFGRVFTNLQLKAIRSKSD
 190 200 210 220 230 240
 KSHVLYFRTTSTVDGKTTILKFEPLQKVCTRQIILALPVFALMQVDWPPLRENRAQKAYG
 250 260 270 280 290 300
 AVRТИPASKVFMFDQFWLQNDVTDFPAFVTKGDTTFSQMYDWKKSEASGDYILIASYA
 310 320 330 340 350 360
 DGNNTLFQRVLRDQGEPINGSEAGAHIVSEPLKNQILDHLADAFGVPRSDIQEPKTAVSK
 370 380 390 400 410 420
 FWTDYFPGCGWITWRAGYHFDDVMNTMRRPSLTDEVYVVGADYSWGLISSWVEGALETSY
 430 440 450 460 470 480
 EVIDTYFKSERSHNVQPPSHMASHVG
 490 500

Fig. 11

Cyplasin-L-(-Sig-Seq.)-Mut

10/501098

13/13




Fig. 12

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.